During the last session, Acer Therapeutics Inc. (NASDAQ:ACER)’s traded shares were 0.19 million, with the beta value of the company hitting 1.50. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday gain of 0.70% or $0.01. The 52-week high for the ACER share is $3.77, that puts it down -161.81 from that peak though still a striking 19.44% gain since the share price plummeted to a 52-week low of $1.16. The company’s market capitalization is $26.22M, and the average intraday trading volume over the past 10 days was 90930.0 shares, and the average trade volume was 148.45K shares over the past three months.
Acer Therapeutics Inc. (ACER) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. ACER has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.57.
Acer Therapeutics Inc. (NASDAQ:ACER) trade information
Acer Therapeutics Inc. (ACER) registered a 0.70% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.70% in intraday trading to $1.44 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 3.20%, and it has moved by 2.86% in 30 days. Based on these gigs, the overall price performance for the year is -40.50%. The short interest in Acer Therapeutics Inc. (NASDAQ:ACER) is 0.15 million shares and it means that shorts have 0.91 day(s) to cover.
The consensus price target of analysts on Wall Street is $9.67, which implies an increase of 85.11% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $12.00 respectively. As a result, ACER is trading at a discount of -733.33% off the target high and -386.11% off the low.
Acer Therapeutics Inc. (ACER) estimates and forecasts
Statistics show that Acer Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Acer Therapeutics Inc. (ACER) shares have gone down -31.43% during the last six months, with a year-to-date growth rate less than the industry average at -221.30% against 11.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -147.80% this quarter and then drop -304.30% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.00%. While earnings are projected to return 47.60% in 2022.
Acer Therapeutics Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Acer Therapeutics Inc. (NASDAQ:ACER)’s Major holders
Acer Therapeutics Inc. insiders own 12.32% of total outstanding shares while institutional holders control 23.07%, with the float percentage being 26.31%. Nantahala Capital Management, LLC is the largest shareholder of the company, while 26 institutions own stock in it. As of Mar 30, 2022, the company held over 0.78 million shares (or 5.08% of all shares), a total value of $2.26 million in shares.
The next largest institutional holding, with 0.28 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 1.82% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $0.81 million.
Also, the Mutual Funds coming in first place with the largest holdings of Acer Therapeutics Inc. (ACER) shares are Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.28 million shares. This amounts to just over 1.81 percent of the company’s overall shares, with a $0.8 million market value. The same data shows that the other fund manager holds slightly less at 58632.0, or about 0.38% of the stock, which is worth about $0.14 million.